Study S001173

A Double-Blind Placebo-Controlled Study of Exenatide for the Treatment of Weight Gain Associated With Olanzapine in Obese Adults With Bipolar Disorder, Major Depressive Disorder, Schizophrenia or Schizoaffective Disorder

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT00845507
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE4
Masking: TRIPLE
Status: COMPLETED
Enrollment: 54
Start: 2008-12
Primary completion: 2015-07
Lead sponsor: University of Cincinnati
Conditions: Weight Gain
Interventions: DRUG:Exenatide; DRUG:Placebo
Results posted: TRUE

Registered primary outcomes

Change in Weight From Baseline to Endpoint. [16 Weeks]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0016174	A double-blind, placebo-controlled trial of exenatide for the treatment of olanzapine-related weight gain in obese and overweight adults. Patino LR, Journal of affective disorders	2025	Randomized trial	PMID 40203970 DOI	cites ClinicalTrials.gov:NCT00845507; registry reference DERIVED:40203970